Analysts Anticipate IDEXX Laboratories, Inc. (NASDAQ:IDXX) to Post $0.91 EPS

Equities research analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings of $0.91 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for IDEXX Laboratories’ earnings, with estimates ranging from $0.90 to $0.93. IDEXX Laboratories posted earnings of $0.98 per share during the same quarter last year, which indicates a negative year over year growth rate of 7.1%. The firm is expected to report its next earnings report on Friday, February 7th.

On average, analysts expect that IDEXX Laboratories will report full year earnings of $4.76 per share for the current year, with EPS estimates ranging from $4.75 to $4.78. For the next year, analysts expect that the company will post earnings of $5.42 per share, with EPS estimates ranging from $5.37 to $5.45. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for IDEXX Laboratories.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.10. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The firm had revenue of $605.30 million during the quarter, compared to analyst estimates of $597.09 million. During the same quarter last year, the business posted $1.05 EPS. The company’s revenue was up 11.0% on a year-over-year basis.

A number of equities analysts recently commented on the stock. Zacks Investment Research lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating and set a $267.00 price objective for the company. in a research note on Monday, November 11th. Guggenheim set a $310.00 price objective on shares of IDEXX Laboratories and gave the stock a “buy” rating in a research note on Friday, November 1st. Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Monday, September 9th. They issued a “neutral” rating and a $277.00 price objective for the company. ValuEngine lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $289.57.

IDEXX Laboratories stock traded up $1.02 during midday trading on Friday, reaching $252.90. The stock had a trading volume of 481,631 shares, compared to its average volume of 508,963. The firm’s fifty day simple moving average is $259.68 and its two-hundred day simple moving average is $270.93. IDEXX Laboratories has a twelve month low of $176.11 and a twelve month high of $294.57. The company has a debt-to-equity ratio of 3.76, a current ratio of 1.12 and a quick ratio of 0.80. The firm has a market cap of $21.61 billion, a price-to-earnings ratio of 59.37 and a beta of 0.72.

In other IDEXX Laboratories news, insider Jonathan W. Ayers sold 36,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $254.05, for a total value of $9,145,800.00. Following the completion of the sale, the insider now owns 947,317 shares in the company, valued at approximately $240,665,883.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Giovani Twigge sold 14,750 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $250.51, for a total transaction of $3,695,022.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,130 shares of company stock valued at $31,118,453. Insiders own 2.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors raised its holdings in shares of IDEXX Laboratories by 32.5% during the 2nd quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock valued at $42,000 after purchasing an additional 37 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of IDEXX Laboratories by 2.0% during the 3rd quarter. Synovus Financial Corp now owns 1,895 shares of the company’s stock valued at $518,000 after purchasing an additional 37 shares in the last quarter. Ropes Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories by 0.5% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 7,293 shares of the company’s stock valued at $2,008,000 after purchasing an additional 38 shares in the last quarter. Western Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 0.7% during the 2nd quarter. Western Wealth Management LLC now owns 5,669 shares of the company’s stock valued at $1,562,000 after purchasing an additional 40 shares in the last quarter. Finally, Colony Group LLC raised its holdings in shares of IDEXX Laboratories by 2.3% during the 3rd quarter. Colony Group LLC now owns 1,924 shares of the company’s stock valued at $523,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 87.03% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.